DLDmytro Ledin

Dmytro Ledin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dmytro Ledin has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    National consensus on reproductive medicine

    by A.V. Kaminskyi, A.V. Serbeniuk, I.V. Malysheva, Y.V. Lukianchenko, M.V. Maistrenko, D.S. Ledin, І.в. Малишева, Ю.в. Лук’янченко

    The objective: to develop and implement a comprehensive, ethically sound, and scientifically validated strategy to ensure access to high-quality reproductive medical services for all citizens in need.Materials and methods. A survey of 553 obstetrician-gynecologists and general practitioners (family medicine) was conducted and analyzed.Results. We conducted a study and analyzed literature sources authored by both domestic and international experts, including guidelines from Ukrainian state institutions and global medical societies specializing in fertility health. Additionally, we carried out a survey of 553 obstetrician-gynecologists and general practitioners – family doctors. The collected data from the literature and our survey were then compared. This study revealed that the majority of physicians choose patient management strategies for infertility in accordance with recommendations from the international medical community.Conclusions. A national consensus on the management of patients with infertility should assist practicing physicians in matters of diagnosis and the development of treatment strategies for this patient cohort.


  • Open Access

    Modern strategies for the prevention and treatment of human papillomavirus

    by Д.г. Коньков, O.V. Tykholaz, D.S. Ledin

    Human papillomavirus (HPV) remains one of the most prevalent sexually transmitted infections worldwide, with high-risk oncogenic types being closely associated with the development of cervical, anogenital, and oropharyngeal cancers. Despite the availability of effective prophylactic vaccines, the widespread persistence of HPV infection, insufficient immunization coverage in certain regions, and the lack of specific antiviral therapy underscore the need to improve strategies for prevention and treatment.To analyze current approaches to the prevention and treatment of HPV infection with an emphasis on the effectiveness of vaccination, therapeutic interventions, and the potential role of interferon therapy – particularly interferon-α-2b – as a promising immunomodulatory agent.This article presents an analytical review of up-to-date publications, clinical guidelines, and recommendations from World Health Organization, Centers for Disease Control and Prevention, and European Centre for Disease Prevention and Control, along with results from randomized clinical trials regarding HPV prevention and treatment. The evidence base for vaccination, local destructive methods, immunostimulatory therapy, and interferon use is summarized and critically evaluated.Prophylactic vaccination remains the most effective tool in preventing infections caused by high-risk HPV types and the associated precancerous lesions. In the treatment of HPV-induced changes, surgical and destructive methods, immunomodulatory agents, as well as experimental therapeutic vaccines that are in the final stages of clinical trials are used. Interferon-α-2b as an immunomodulator has demonstrated the ability to stimulate antiviral immune responses, promote the regression of cervical intraepithelial neoplasia, and reduce recurrence rates in patients with persistent HPV infection.Modern strategies for HPV management should be comprehensive, combining vaccination, regular screening, timely lesion detection, and personalized treatment approaches, including immunomodulatory therapies. Further clinical studies on the use of interferon-α-2b are warranted to expand therapeutic options for patients with persistent HPV-related disease.


  • Mathematical model for predicting adverse perinatal outcomes in women with COVID-19

    by R.M. Savchuk, D.S. Ledin, O.I. Zhdanovych, T.V. Kolomiichenko, R.I. Zhdanovych

    The aim: to create a mathematical model for predicting adverse perinatal outcomes in women with COVID-19. Materials and methods. To build a mathematical prediction model, candidate indicators were selected whose frequency significantly differed in the groups of pregnant women with significant perinatal disorders (group O1, n=50) and without such disorders (group O2, n=150), and odds ratio (OR) calculations were performed. To assess the significance of the indicators in points and assign threshold values, the expert evaluation method, the Delphi method, was used. Results. The most statistically significant indicators for predicting perinatal disorders in pregnant women with COVID-19 are laboratory indicators associated with COVID-19, indicators of disease severity, stress, the presence of anxiety and depression, and endocrine pathology. The constructed model (scale) for predicting perinatal disorders in pregnant women with COVID-19 includes 24 indicators and can be used in 2 stages: 1 - at the prehospital stage and/or at the beginning of hospitalization (9 indicators), 2 - in the dynamics of the disease at the hospital stage (15 indicators). The ease of use (scoring), as well as the established fairly high accuracy (86.7%), sensitivity (87.5%), and specificity (86.4%) of the prediction model, allow us to recommend it for use in clinical practice. Conclusions. The implementation of a model for predicting perinatal disorders in pregnant women with COVID-19 for the purpose of early identification of high-risk patients, their timely hospitalization, and treatment will reduce the incidence of perinatal complications, morbidity, and mortality of the mother and child. The research was carried out in accordance with the principles of the Declaration of Helsinki. The study protocol was approved by the Local Ethics Committee of the institution mentioned in the paper. The informed consent of the patient was obtained for conducting the studies. No conflict of interests was declared by the authors.


  • Open Access

    MODEL FOR PREDICTION AND PREVENTION OF ADVERSE PERINATAL OUTCOMES IN COVID-19 IN WOMEN

    by R. M. Savchuk, D. S. Ledin, T. V. Kolomiichenko

    Relevance. The task of developing a model for predicting and preventing adverse perinatal outcomes in women with COVID-19 is relevant, which should provide an effective clinical solution taking into account individual and regional characteristics, which will contribute to reducing maternal and perinatal morbidity and mortality. Purpose. To create a tool for early identification of pregnant women with a high risk of complications in case of COVID-19 to reduce maternal and perinatal mortality, prevent adverse perinatal complications (using the example of Ivano-Frankivsk region).Materials and methods. The creation of a model for predicting and preventing adverse perinatal outcomes in case of COVID-19 in women is based on research using the bibliosemantic research method, the method of structural-logical analysis, analytical, statistical and conceptual methods, clinical, anamnestic and laboratory-instrumental methods, and questionnaires. Results. The medical and social justification, principles of formation and expected results of the implementation of the model of prediction and prevention of adverse perinatal consequences of COVID-19 in women are presented. The development and implementation of such a model can be carried out in 5 stages over 3 years: preparatory and analytical (1–2 quarters of the 1st year); creation and testing of a digital model (3–4 quarters of the 1st year); pilot implementation in the region (1–2 quarters of the 2nd year); scaling and integration (3–4 quarters of the 2nd year); effectiveness assessment and continuous improvement (3rd year and beyond). Model components: screening stage (at the primary level); prediction stage (secondary level); response stage (tertiary level); information support and monitoring. Conclusions. The practical implementation of the developed model allows improving the quality of medical care for pregnant women during the pandemic, optimizing the use of healthcare system resources, reducing the incidence of complications and improving perinatal outcomes even in conditions of limited resources. Актуальність. Актуальним є завдання розробки моделі прогнозування і профілактики несприятливих перинатальних наслідків у жінок із COVID-19, яка має забезпечити ефективне клінічне рішення з урахуванням індивідуальних та регіональних особливостей, що сприятиме зниженню материнської і перинатальної захворюваності та смертності. Мета. Створити інструмент для ранньої ідентифікації вагітних із високим ризиком ускладнень у разі COVID-19 для зниження материнської та перинатальної смертності, попередження несприятливих перинатальних ускладнень (на прикладі Івано-Франківської області). Матеріали та методи.Створення моделі прогнозування і профілактики несприятливих перинатальних наслідків при COVID-19 у жінки базується на проведених дослідженнях з використанням бібліосемантичного методу дослідження, метод структурно-логічного аналізу, аналітичний, статистичний та концептуальний методи, клінічні, анамнестичні та лабораторно-інструментальні методи, анкетування. Результати. Наведено медико-соціальне обґрунтування, принципи формування та очікувані результати впровадження моделі прогнозування і профілактики несприятливих перинатальних наслідків при COVID-19 у жінки. Розробка і впровадження такої моделі може здійснюватись у 5 етапів за 3 роки: підготовчо-аналітичний (1–2 квартал 1-го року); створення і тестування цифрової моделі (3–4 квартал 1-го року); пілотне впровадження в регіоні (1–2 квартал 2-го року); масштабування та інтеграція (3–4 квартал 2-го року); оцінка ефективності та постійне вдосконалення (3-й рік рік і далі). Компоненти моделі: етап скринінгу (на первинному рівні); етап прогнозування (вторинний рівень); етап реагування (третинний рівень); інформаційна підтримка та моніторинг. Висновки. Практичне впровадження розробленої моделі дозволяє покращити якість медичної допомоги вагітним у період пандемії, оптимізувати використання ресурсів системи охорони здоров’я, знизити частоту ускладнень та підвищити перинатальні результати навіть в умовах обмежених ресурсів.


  • Open Access

    Peculiarities of intrauterine pathological processes in women of the postmenopauseal period

    by Tetiana Polishchuk, Serhii Vdovichenko, Oleksandra Lubkovska, Dmytro Ledin

    Aim of the research is studying the pecularities of the endometrium pathological processes in postmenopausal women on the basis of the hysteroscopy data evaluation, as well as conduction of histopathological and immunochemical studies. Materials and methods. To study the pecularities of intrauterine pathological processes, 100 postmenopausal women were selected and studied. All women underwent hysteroscopy with separate diagnostic scraping of the uterine cavity. Also, 10 samples of glandular-fibrous endometrial polyps (GFEP) in women of reproductive age and 9 samples of such pathology in the postmenopausal period were studied by immunohistochemical method, using 6 primary specific monoclonal antibodies. Results. The results showed that in 64 (64 %) postmenopausal women pathological changes of the endometrium were presented with GFEP, and in 2 patients (2 %) endometrial adenocarcinoma was found. It was also determined that the nuclei of epithelial and stromal cells of GFEP in postmenopausal women are characterized by lower expression of estrogen and progesterone receptors, compared with women with such formations in the reproductive age. In addition, it was found that in postmenopausal women the expression of the apoptosis inhibitor bcl-2 and aromatase P450 in the epithelial and stromal cells of GFEP was more expressed, and the expression of the Bах antigen, on the contrary, was significantly lower than in women of reproductive age. Conclusions. Fundamental molecular-biological differences of GFEP in postmenopausal women compared with women of reproductive age were revealed. It was found that in postmenopausal women there is a significantly lower dependence of such polyps on the effects of estrogen and progesterone. In addition, the data indicate an increased risk of neoplastic transformation in such women.

  • Open Access

    VULVOVAGINAL CANDIDIASIS IN COMBINATION WITH BACTERIAL VAGINOSIS IN WOMEN OF REPRODUCTIVE AGE: FEATURES OF PATHOGENESIS AND TREATMENT

    by Svitlana Pandei, Dmytro Ledin, Oleksandra Lubkovska

    The aim. Reducing the recurrence of vulvovaginal candidiasis (VVC) in combination with bacterial vaginosis (BV) in women of reproductive age by studying the pathogenesis and improving the algorithm of treatment and prevention measures. Materials and methods. During the study, 150 women of reproductive age who had the same clinical manifestations of VVC and BV were selected and divided into 3 groups of 50 women: Group I was treated with an antimicrobial combination drug (miconazole with topical metronidazole), group II – the same drug in combination with probiotic (lactobacilli) in candles, group III – according to the algorithm improved by the authors. In addition, a control group was formed, which included healthy women of reproductive age. To establish the pathogenesis of VVC in combination with BV in the studied women, the concentration of cytokines and adhesion molecules in the blood before and after treatment was determined and compared with the control group. The clinical effect of different treatments was assessed at 3, 7, 10, 14 days, and the presence of relapses – 1, 3, 6 months after treatment. Results. The occurrence of a combination of VVC and BV in women of reproductive age is accompanied by a significant increase in the level of intercellular adhesion molecules (ICAM-1) and vascular cell adhesion molecules (VCAM-1) along with a statistically significant increase in proinflammatory cytokines (interleukin-6) (IL-6), interleukin-8 (IL-8)) and tumor necrosis factor (TNF) - TNF-α. As a result of the application of the algorithm improved by the authors, higher clinical efficiency and the ability to avoid recurrence of VVC in combination with BV in women of reproductive age were obtained. Conclusions. The authors' substantiated improvement of the algorithm of VVC treatment in combination with BV in women of reproductive age makes it possible to reduce the frequency of their recurrence and restore the biocenosis of the vagina to normal. In the case of this pathology there is an increase in the level of pro-inflammatory cytokines (IL-6, IL-8), TNF-α and ICAM-1 and VCAM-1.